Denmark's Netcompany has been awarded a five-year contract from NHS England, worth more than £215 million, to build the ...

Shares in rare disease specialist Ultragenyx lost nearly 47% of their value after the announcement, more than wiping out ...

Shares in China's Hutchmed surged today after GSK paid $110 million upfront for rights to a preclinical-stage KRAS and EGFR-targeted drug with potential in colorectal, pancreatic, and lung cancer.

Boehringer Ingelheim has joined Sanofi and AstraZeneca in signing up to deploy Owkin's AI platform K Pro in its drug ...

The US Advanced Research Projects Agency for Health (ARPA-H) has awarded $125 million in funding, split across five groups, ...

The US FDA issued similar warning letters to five different online peptide vendors on 24th August, giving the companies 15 ...

Shares in the UK's IP Group slid today after it revealed that an arthritis drug in development at one of its portfolio companies, Istesso, had failed a phase 2b trial. The early-stage investor in life ...

MHRA's first two centralised programmes are focusing on software or AI used as a medical device (SaMD/AIaMD) and the use of ...

Novartis has paused eight clinical trials of its experimental CAR-T therapy rapcabtagene autoleucel (rap-cel or YTB323) after ...

PMV Pharma is preparing to file for approval of its oral p53 protein reactivator drug rezatopopt in the first quarter of 2027 ...

Custom autologous cell therapies face immense manufacturing bottlenecks, steep financial costs, and vein-to-vein logistical ...

Roche is paying $75 million for a trispecific antibody developed by a subsidiary of China's Simcere Pharma as a treatment for ...